Long-term efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor1,4,5 modulator, for moderate-to-severe atopic dermatitis: Results from the open-label extension of the phase II ADVISE study

Authors
Category Primary study
ConferenceBritish Journal of Dermatology
Year 2022
This article has no abstract
Epistemonikos ID: 87dcffcf655196a59278641a8bcc88300874db4b
First added on: Apr 30, 2026